Literature DB >> 2869742

Persistent tardive dyskinesia in bipolar patients.

S Mukherjee, A M Rosen, G Caracci, S Shukla.   

Abstract

The prevalence and outcome of persistent tardive dyskinesia (TD) was studied in 131 bipolar patients. There were 34 cases of persistent TD in the subgroup (n = 96) with a history of neuroleptic treatment (prevalence, 35.4%; 95% confidence interval, 25% to 45%); there were no cases of persistent TD in the subgroup (n = 35) without such treatment history. Except in one patient, signs of TD persisted in spite of lithium carbonate treatment in 23 patients (median duration, 16 months; range, five to 24 months), of whom 15 remained off of a neuroleptic regimen during the study period for a median duration of 14 months (range, four to 24 months). Using multiple regression analysis, two variables were found to predict the presence of persistent TD and account for 36% of the variance: longer cumulative duration of maintenance neuroleptic treatment and shorter duration of previous lithium carbonate treatment. There appears to be a significant risk of persistent TD among neuroleptic-treated bipolar patients. High-risk subgroups within this category need to be identified.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2869742     DOI: 10.1001/archpsyc.1986.01800040052008

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  11 in total

Review 1.  Medication-Induced Tardive Dyskinesia: A Review and Update.

Authors:  Elyse M Cornett; Matthew Novitch; Alan David Kaye; Vijay Kata; Adam M Kaye
Journal:  Ochsner J       Date:  2017

2.  Neurobiological characterization of bipolar affective disorders : a focus on tardive dyskinesia and soft neurological signs in relation to serum dopamine Beta hydroxylase activity.

Authors:  U Goswami; S Basu; U Khastgir; U Kumar; R Chandrasekaran; B N Gangadhar; R Sagar; J S Bapna; S M Channabasavanna; P B Moore; I N Ferrier
Journal:  Indian J Psychiatry       Date:  1998-07       Impact factor: 1.759

Review 3.  Tardive dyskinesia.

Authors:  T R Barnes
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-16

Review 4.  Managing bipolar disorder in the elderly: defining the role of the newer agents.

Authors:  Martha Sajatovic; Subramoniam Madhusoodanan; Nicoleta Coconcea
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 5.  Atypical antipsychotics and mood stabilization in bipolar disorder.

Authors:  Paolo Brambilla; Francesco Barale; Jair C Soares
Journal:  Psychopharmacology (Berl)       Date:  2003-02-27       Impact factor: 4.530

Review 6.  Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis.

Authors:  Jorge M Tamayo; Carlos A Zarate; Eduard Vieta; Gustavo Vázquez; Mauricio Tohen
Journal:  Int J Neuropsychopharmacol       Date:  2010-02-04       Impact factor: 5.176

7.  The use of atypical antipsychotics in Bipolar Spectrum disorders.

Authors:  H Grünze; H J Möller
Journal:  Indian J Psychiatry       Date:  2003-01       Impact factor: 1.759

8.  A comparative study of neuroleptic induced neurological side effects in schizophrenia and mood disorders.

Authors:  P N Kumar; T M Kumar
Journal:  Indian J Psychiatry       Date:  1997-04       Impact factor: 1.759

Review 9.  The behavioral actions of lithium in rodent models: leads to develop novel therapeutics.

Authors:  Kelley C O'Donnell; Todd D Gould
Journal:  Neurosci Biobehav Rev       Date:  2007-04-13       Impact factor: 8.989

10.  [Drug therapy of acute manias. A retrospective data analysis of inpatients from 1997 to 1999].

Authors:  M Letmaier; D Schreinzer; N Thierry; R Wolf; S Kasper
Journal:  Nervenarzt       Date:  2004-03       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.